Results 151 to 160 of about 47,536 (295)

SPARCL1 and NT‐proBNP as biomarkers of right ventricular‐to‐pulmonary artery uncoupling in pulmonary hypertension

ESC Heart Failure, Volume 12, Issue 2, Page 1416-1426, April 2025.
Abstract Aims SPARCL1 was recently identified as a biomarker of right ventricular (RV) maladaptation in patients with pulmonary hypertension (PH), and N‐terminal pro‐brain natriuretic protein (NT‐proBNP) is an established biomarker of RV failure in PH. The present study investigated whether NT‐proBNP and SPARCL1 concentrations are associated with load ...
Oliver Dörr, Stanislav Keranov, Paulina van Wickern, Holger Nef, Christian Hamm, Pascal Bauer, Christian Troidl, Samuel Sossalla, Sandra Voss, Christoph Liebetrau, Manuel J. Richter, Henning Gall, Werner Seeger, Ardeschir Ghofrani, Athiththan Yogeswaran, Khodr Tello   +15 more
wiley   +1 more source

Rethinking natriuretic peptides: hypoxia and haemoconcentration in atrial fibrillation. [PDF]

Heart
Arjamaa O.
europepmc   +1 more source

Mortality risk stratification for Takotsubo syndrome: Evaluating CRP measurement alongside the InterTAK prognostic score

ESC Heart Failure, Volume 12, Issue 2, Page 1427-1436, April 2025.
Abstract Background and objectives Initially described as a benign acute cardiomyopathy, Takotsubo syndrome has been linked to elevated mortality rates. Emerging evidence suggests that unresolved myocardial inflammation may contribute to this adverse prognosis.
Loïc Faucher, Kensuke Matsushita, Shinnosuke Kikuchi, Taraneh Tatarcheh, Benjamin Marchandot, Amandine Granier, Said Amissi, Antonin Trimaille, Laurence Jesel, Patrick Ohlmann, Kiyoshi Hibi, Valérie Schini‐Kerth, Olivier Morel   +12 more
wiley   +1 more source

Early neurological rehabilitation management in a stroke patient with persistently and extremely elevated natriuretic peptides: a case report. [PDF]

Front Med (Lausanne)
Han X, Huang Z.
europepmc   +1 more source

Atrial natriuretic factor in plasma of patients with arterial hypertension, heart failure or cirrhosis of the liver [PDF]

, 1986
Arendt, Rainer M., Bach, Peter, Gerbes, Alexander L., Ritter, Detlef, Stangl, Elisabeth, Zähringer, Josef   +5 more
core   +1 more source

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad, Jeanne du Fay de Lavallaz, Michael J. Zhang, Thanat Chaikijurajai, Bo Ye, Prabhjot S. Nijjar, Julie A. Lahiri, Cindy M. Martin, Tamas Alexy, Markus Meyer   +9 more
wiley   +1 more source

Natriuretic peptides as novel regulators of dendritic cells-mediated inflammation. [PDF]

Cell Mol Life Sci
Manni G, Barcelos ECS, Ricciuti D, Pieroni B, Gargaro M, Mencarelli G, Acha-Orbea H, Talesa VN, Mezzasoma L, Fallarino F.   +9 more
europepmc   +1 more source

B-Type Natriuretic Peptides Levels in Patients With Beta-Thalassemia Major and Correlations With Biomarkers: A Systematic Review and Meta-Analysis. [PDF]

Health Sci Rep
Salih MSK, Mohamed AH, Mirghani EMA, Makki MYK, Ahmed OAM, Mohammed ETS, Hassan HHM, Omar N, Garalnabi EMA, Mohamed SOO.   +9 more
europepmc   +1 more source

Economic evaluation of the routine use of echocardiography versus natriuretic peptide and ECG-targeted echocardiography in the diagnosis of heart failure [PDF]

Objectives: To investigate the most efficient use of echocardiography and natriuretic peptide testing in the diagnosis of heart failure. Design: An economic model comparing two strategies: (A) provide echocardiography and electrocardiogram (ECG) for ...
Cowie, M.R., Roberts, J., Stevenson, M.
core  

Mapping the Global Clinical Landscape of Pharmacological Therapies for Heart Failure With Preserved Ejection Fraction: An Analysis Based on ClinicalTrials.gov (2003–2025)

iMetaMed, EarlyView.
This study analyzed 236 heart failure with preserved ejection fraction (HFpEF) pharmacological trials registered on ClinicalTrials.gov from 2003 to 2025, revealing a post‐2016 surge (76.3%), U.S. dominance (58.5%), and prominence of SGLT2 inhibitors/novel therapies (each 13.1%).
Yucheng Hou, Jingwei Zhao, Yuqian Tang, Tan Liu, Zhiao Zhang, Ziheng Wang, Han Shen   +6 more
wiley   +1 more source